Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery

NCT05914792 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 49

Last updated 2025-04-10

No results posted yet for this study

Summary

This prospective study recruits patients with ER+/HER2-, non-metastatic breast cancer who omit upfront surgery in favor of primary endocrine therapy for sample collection and prospective circulating tumor DNA (ctDNA) measurement to guide disease surveillance.

Conditions

Sponsors & Collaborators

  • Natera, Inc.

    collaborator INDUSTRY
  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Priscilla McAuliffe, MD, PhD · UPMC Magee Women's Hospital, UPMC Hillman Cancer Center

Eligibility

Min Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-19
Primary Completion
2024-10-16
Completion
2026-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05914792 on ClinicalTrials.gov